Ayala Pharmaceuticals Inc Quick Ratio (ADXS) starting from the fourth quarter 2023 to fourth quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Ayala Pharmaceuticals Inc   (ADXS)

Ayala Pharmaceuticals Inc 's Quick Ratio

ADXS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2023, Quick Ratio fell to 0.2 below Ayala Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 535 other companies have achieved higher Quick Ratio than Ayala Pharmaceuticals Inc in fourth quarter 2023. While Quick Ratio total ranking has improved so far during the Q4 2023 to 4152, from total ranking in the third quarter 2023 at 4386.

Explain Quick Ratio?
How much Cash & cash equivalents ADXS´s has?
What are ADXS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ADXS Quick Ratio (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4
Y / Y Current Liabilities Change 302.67 % 270.26 % 342.13 % 315.42 % 67.06 %
Y / Y Cash & cash equivalent Change 85.77 % -91.17 % -74.48 % -47.18 % -92.8 %
Quick Ratio MRQ 0.2 0.26 0.85 1.72 0.42
ADXS's Total Ranking # 4152 # 4386 # 2587 # 1361 #
Seq. Current Liabilities Change 193.4 % 1.19 % -14.3 % 58.26 % 169.78 %
Seq. Cash & cash equivalent Change 119.42 % -69.03 % -57.6 % 544.86 % -89.57 %



Quick Ratio fourth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 536
Healthcare Sector # 1036
Overall Market # 4152


Quick Ratio Statistics
High Average Low
28.85 6.25 0
(Oct 31 2015)   (Jul 31 2013)




Financial Statements
Ayala Pharmaceuticals Inc 's Current Liabilities $ 25 Millions Visit ADXS's Balance sheet
Ayala Pharmaceuticals Inc 's Cash & cash equivalent $ 5 Millions Visit ADXS's Balance sheet
Source of ADXS's Sales Visit ADXS's Sales by Geography


Cumulative Ayala Pharmaceuticals Inc 's Quick Ratio

ADXS's Quick Ratio for the trailling 12 Months

ADXS Quick Ratio

 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth 305.07 % 220.54 % 68.7 % 21.83 % -27.12 %
Y / Y Cash & cash equivalent TTM Growth -64.53 % -76.23 % -62.43 % -53.08 % -48.63 %
Quick Ratio TTM 0.6 0.88 1.94 3.6 6.89
Total Ranking TTM # 3991 # 2473 # 5625 # 3482 #
Seq. Current Liabilities TTM Growth 56.98 % 23.24 % 32.19 % 58.38 % 24.23 %
Seq. Cash & cash equivalent TTM Growth 7.78 % -44.23 % -28.75 % -17.19 % -27.77 %

Quick ratio ranking by company, industry and sector >> Back to ADXS Financial Strength Comparisons >> Go to Compare ADXS Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q4 2023 to $25.02 millions, cumulative Quick Ratio decreased to 0.6 below the Ayala Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 487 other companies have achieved higher Quick Ratio than Ayala Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2023 from 2473 to 3991.

Explain Quick Ratio?
How much Cash & cash equivalents ADXS´s has?
What are ADXS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 488
Healthcare Sector # 989
Within the Market # 3991


trailing twelve months Quick Ratio Statistics
High Average Low
11.84 5.32 0.6
(Oct 31 2022)   (Dec 31 2023)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Opko Health Inc   0.54 $ 95.881  Millions$ 178.687  Millions
Ascendis Pharma A  0.53 $ 434.699  Millions$ 814.726  Millions
Nurix Therapeutics Inc   0.53 $ 54.627  Millions$ 102.466  Millions
Lexaria Bioscience Corp   0.52 $ 0.126  Millions$ 0.240  Millions
Camp4 Therapeutics Corporation  0.52 $ 38.169  Millions$ 73.375  Millions
Altamira Therapeutics Ltd   0.52 $ 0.734  Millions$ 1.412  Millions
Lftd Partners Inc   0.51 $ 4.401  Millions$ 8.687  Millions
Neurosense Therapeutics Ltd  0.50 $ 2.680  Millions$ 5.368  Millions
Bristol myers Squibb Company  0.50 $ 12,280.000  Millions$ 24,633.000  Millions
Lifecore Biomedical Inc   0.49 $ 19.091  Millions$ 39.289  Millions
Novartis Ag  0.48 $ 13,819.000  Millions$ 28,581.000  Millions
Jaguar Health Inc   0.46 $ 6.469  Millions$ 13.987  Millions
Protokinetix Incorporated  0.46 $ 0.020  Millions$ 0.045  Millions
Dar Bioscience Inc   0.45 $ 10.476  Millions$ 23.241  Millions
Biophytis Sa  0.45 $ 6.235  Millions$ 13.849  Millions
Actuate Therapeutics Inc   0.45 $ 2.959  Millions$ 6.643  Millions
Akebia Therapeutics Inc   0.43 $ 42.925  Millions$ 99.870  Millions
Entrada Therapeutics Inc   0.43 $ 67.602  Millions$ 158.796  Millions
Mustang Bio inc   0.42 $ 6.234  Millions$ 14.756  Millions
Evoke Pharma Inc   0.42 $ 4.739  Millions$ 11.309  Millions
Optinose Inc   0.42 $ 73.684  Millions$ 176.524  Millions
Bio Green Med Solution Inc   0.41 $ 3.378  Millions$ 8.161  Millions
Sonnet Biotherapeutics Holdings Inc   0.41 $ 2.274  Millions$ 5.525  Millions
Hcw Biologics Inc   0.41 $ 3.595  Millions$ 8.748  Millions
Pharming Group N v   0.41 $ 61.741  Millions$ 150.496  Millions
Elanco Animal Health Incorporated  0.40 $ 352.000  Millions$ 874.000  Millions
Intelgenx Technologies Corp   0.40 $ 2.357  Millions$ 5.866  Millions
Bausch Health Companies Inc   0.39 $ 947.000  Millions$ 2,435.000  Millions
Cellectar Biosciences Inc   0.38 $ 9.565  Millions$ 25.300  Millions
Prestige Consumer Healthcare Inc   0.36 $ 58.489  Millions$ 160.715  Millions

Date modified: 2026-09-08T15:11:19+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.